Landing, NJ—Results from a new clinical study published in The Journal of Traditional and Complementary Medicine show that Bergacyn, a botanical extract blend marketed by DolCas Biotech, has beneficial effects on reducing liver steatosis, inflammation and oxidative stress in type 2 diabetes, according to a press release.
The 16-week, randomized, double-blind study divided 80 subjects into four treatment subgroups: placebo; 600mg Bergacyn; 600 mg of a stand-alone bergamot extract blend; and an equivalently dosed cynara extract blend, according to the release.
The results showed significant changes in fatty liver acid for the Bergacyn group compared to the placebo group: Fatty liver accumulation regressed two levels, from severe to mild, the release noted.
Related: 8 Supplements for Detox and Liver Health
Green Tea + Exercise = Healthy Liver, Study Suggests
Veggie Compound May Help Control NAFLD, Study Finds
In addition, in the Bergacyn group as compared to the placebo group, AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels reduced; there was an increase in antioxidation and fibrosis intervention (via reduced scar tissue mediators) and anti-inflammatory action.
Steatosis affects 25% of people globally and has doubled each decade since 1988; paralleled with the obesity epidemic in the US, Non Alcoholic Fatty Liver Disease (NAFLD) is projected to cost Americans over one trillion dollars, according to the release.
“Bergacyn’s unique blending of a high-polyphenol extract of bergamot and a high-sesquiterpene extract of artichoke leaf showed a novel synergistic benefit that was more than additive, when compared to stand-alone, single doses of bergamot or cynara extract,” explains Dr. Shavon Jackson-Michel, Director of Medical and Scientific Affairs for DolCas in the press release.